Vistagen & everinsight enter strategic collaboration to develop and commercialize ph94b

Vistagen therapeutics and everinsight therapeutics enter strategic collaboration to develop and commercialize ph94b for anxiety disorders in greater china, south korea and southeast asia.vistagen therapeutics - collaboration intended to support phase 3 development and commercialization of ph94b in key asian markets.vistagen therapeutics inc - agreement includes $5 million upfront payment and development and commercial milestones up to $172 million.
VTGN Ratings Summary
VTGN Quant Ranking